Publisher
Springer Science and Business Media LLC
Reference26 articles.
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.
2. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: ovarian cancer including fallopian tube cancer and primary peritoneal cancer. 2023. https://www.nccn.org. Accessed 31 Jan 2024.
3. Garzon S, Lagana AS, Casarin J, et al. Secondary and tertiary ovarian cancer recurrence: what is the best management? Gland Surg. 2020;9(4):1118–29.
4. Randall LM, Monk BJ. Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol. 2010;117(3):497–504.
5. Gaillard S, Oaknin A, Ray-Coquard I, et al. Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: a multicenter, randomized, controlled, open-label phase 3 study (CORAIL). Gynecol Oncol. 2021;163(2):237–45.